ABBOTT A Growth & Income Investment JP Morgan Healthcare Conference January 11, 2016 Brian Yoor, Senior Vice President, Finance and Chief Financial Officer 1
FORWARD LOOKING STATEMENT Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward- looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,’’ to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2014, and in the interim reports filed on Form 10-Q for subsequent quarterly periods, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 2
TOP-TIER GROWTH & INCOME INVESTMENT Global Performance Balance Relevance Presence Well-balanced Leadership One of the most Top-tier growth, diversity across positions in globalized steady margin our businesses, businesses that healthcare expansion, geographies, are aligned with companies with strong cash flow, and mix of major trends strong positions in increasing payers and the broader both developed returns to global and emerging shareholders environment markets 3
LEADING WITH #1 worldwide in adult nutrition SOLUTIONS ACROSS #1 in U.S. pediatric nutrition THE SPECTRUM World’s 1 st bioresorbable scaffold OF HEALTH World’s leading mitral valve repair device #1 in LASIK; #2 in cataract #2 Pharma Co. in India Top 10 Pharma Co. in Latin America and Russia #1 in blood screening Leading diagnostics platforms 4
ALIGNED WITH TRENDS Growth in emerging markets Investing in health care Emerging middle class Aging population globally 5
ALIGNED WITH TRENDS Source: HBR ‘Prospects for Em erging Markets Aren’t as Bad as You’ve Heard’ (12/ 3/ 20 15) 6 Source: World Health Organization, BMI Research and Haver
MEETING GROWING HEALTH NEEDS IN DEVELOPED AND DEVELOPING MARKETS 50% 50% OF SALES IN OF SALES DIRECTLY EMERGING TO CONSUMERS MARKETS 7
OUR GLOBAL IDENTITY life. to the fullest. • Build a highly recognizable brand • Our customer base is increasingly consumer-facing • Connect with the people who use our products • Cover the entire spectrum of care 8
BROAD AND BALANCED PORTFOLIO ESTABLISHED DIAGNOSTICS NUTRITION MEDICAL DEVICES PHARMACEUTICALS 23% 34% 27% 16% of sales of sales of sales of sales 9
Nutrition UNIQUELY BALANCED FOR GROWTH Adult Pediatric • 45% Emerging; 55% Developed • 45% Adult; 55% Pediatric • #1 Adult Nutrition globally • #1 Pediatric in U.S.; other geographies STRATEGIC PRIORITIES Operating Margin • Capture share with innovation 25% 21.0% 18.7% 20% • Grow and shape markets 15.8% 13.2% 15% • Expand operating margin 10% • Invest for sustainable growth 5% 0% 2011 2012 2013 2014 10
Branded Generic Pharmaceuticals RESHAPED FOR GROWTH Russia India Latin America Other • CFR builds presence in Latin America Emerging • Veropharm builds presence in Russia Markets STRATEGIC PRIORITIES • Strengthening local presence and capabilities • Building locally-relevant portfolios in key therapeutic areas 11
Medical Devices INNOVATION DRIVING Vision EXPANSION Care Vascular Innovation-driven businesses Diabetes Care VASCULAR • Driving uptake of MitraClip, Supera and Absorb DIABETES CARE • Highly differentiated FreeStyle Libre device VISION CARE • Winning in Cataract with new products and market expansion 12
Diagnostics Point of Care DURABLE GROWTH BUSINESS Molecular Core • Leading core lab platforms Laboratory • Leading point-of-care platform • Best-in-class molecular tests STRATEGIC PRIORITIES • Execute Commercial Strategy • Expand in priority emerging markets • Improve margins • Launch next-generation platforms 13
Abbott GROWTH AND INCOME • Broad and Balanced • Leadership • Aligned with Trends • Top-tier Growth and Income • Steady Margin Expansion • Strong Cash Flow • Increasing Returns to Shareholders 14
Recommend
More recommend
